mirumpharma.com (MIRM): Prakiraan wutah bathi resik saben saham kanggo taun ngarep

The forward net income growth rate reflects expert expectations, where 91.90 becomes the new value for this metric. Mirum Pharmaceuticals (MIRM) maintains high pricing power and guaranteed insurance payouts due to its monopoly position in the therapy of rare liver pathologies. Growth is driven by the success of Livmarli and the integration of new assets, while business resilience is supported by the medical community's recognition of its treatment methods.
Mirum Pharma - rincian analitis lan metrik utama (MIRM)

To protect capital amid uncertainty, assessing the annual EPS growth for the next period is critical, as it measures the expected earnings per share dynamics relative to current values. This indicator reflects the ability of Mirum Pharmaceuticals (MIRM) to monetize the success of Livmarli and the integration of new assets, transforming the expansion of therapeutic indications into real growth in shareholder value.